How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

Title
How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 35, Issue 20, Pages 2229-2231
Publisher
American Society of Clinical Oncology (ASCO)
Online
2017-05-05
DOI
10.1200/jco.2016.71.8072

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now